Nubeqa for non-metastatic castration-resistant prostate cancer, approved by FDA
The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer.
Approval was based on ARAMIS, a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer.
Patients were randomized ( 2:1 ) to receive either 600 mg Darolutamide orally twice daily ( n=955 ) or matching placebo ( n=554 ).
All patients received a gonadotropin-releasing hormone ( GnRH ) analog concurrently or had a previous bilateral orchiectomy.
Twelve patients with previous seizure histories were treated on the Darolutamide arm.
The primary endpoint was metastasis free survival ( MFS ), defined as the time from randomization to first evidence of distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first.
The median MFS was 40.4 months ( 95% CI: 34.3, not reached ) for patients treated with Darolutamide compared with 18.4 months ( 95% CI: 15.5, 22.3 ) for those receiving placebo ( hazard ratio, HR=0.41; 95% CI: 0.34, 0.50; p less than 0.0001 ).
Overall survival ( OS ) data were not mature.
The most common adverse reactions ( greater than or equal to 2% ) in patients who received Darolutamide were fatigue, pain in extremity, and rash.
Ischemic heart disease ( 4.3% ) and heart failure ( 2.1% ) were more common on the Darolutamide arm.
The seizure incidence was similar on the two arms ( 0.2% ).
The recommended Darolutamide dose is 600 mg ( two 300 mg tablets ) administered orally twice daily with food.
Patients should also receive a gonadotropin-releasing hormone ( GnRH ) analog concurrently or should have had bilateral orchiectomy. ( Xagena )
Source: FDA, 2019
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...
The FDA ( U.S. Food and Drug Administration ) has approved Isturisa ( Osilodrostat ) oral tablets for adults with...
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...
Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
First-line treatment of EGFR-mutated non-small cell lung cancer: concurrent Osimertinib plus Gefitinib
First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell...
Newly diagnosed primary central nervous system lymphoma: Ibrutinib-based combination therapy has exhibited therapeutic benefit
Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma...
FDA has approved Emgality, the first treatment for episodic cluster headache that reduces the frequency of attacks
The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for...